No Data
No Data
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Goldman Sachs Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $31
Goldman Sachs analyst Chris Shibutani maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 44.9% and a
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
Consumer price index data this week provided encouraging signs that American inflation is moving ever closer to the Federal Reserve's much-discussed 2% target.This fueled speculation about interest
Pfizer Options Spot-On: On July 12th, 180.09K Contracts Were Traded, With 2.9 Million Open Interest
On July 12th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 180.09K options for the day, of which put options accounted for 33.57% of the total transactions, and
Unusual Options Activity: RDDT, GXO and Others Attract Market Bets, RDDT V/OI Ratio Reaches 200.2
EST Jul 12th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
What the 2000's Tech Bubble Says About Today's Suspected Rotation - Analyst
loading...
No Data